Fosun Pharma's subsidiary, BioNTech to set up JV for Covid-19 vaccine production
Fosun Pharmaceutical Industrial will provide a manufacturing facility with an annual capacity of up to 1 billion doses of BioNTech's Covid-19 vaccine
Syringes are seen in front of a displayed Biontech logo in this illustration taken November 10, 2020. REUTERS/Dado Ruvic/Illustration
China's Shanghai Fosun Pharmaceutical said on Sunday its subsidiary had agreed to set up a joint venture with BioNTech for the manufacture and commercialisation of the German firm's Covid-19 vaccine.
Fosun Pharmaceutical Industrial will provide a manufacturing facility with an annual capacity of up to 1 billion doses of BioNTech's Covid-19 vaccine, while BioNTech agreed to license relevant manufacturing technology and know-how to the JV, in which the two firms will hold 50% stake each, Shanghai Fosun Pharma said in a filing.
Keep updated, follow The Business Standard's Google news channel
